Drug-Loaded Polymeric Nanoparticles for Cancer Stem Cell Targeting by Binbin Li et al.
fphar-08-00051 February 10, 2017 Time: 14:46 # 1
REVIEW
published: 14 February 2017
doi: 10.3389/fphar.2017.00051
Edited by:
Amit K. Tiwari,
University of Toledo, USA
Reviewed by:
Alessandro Isidori,
Aormn Hospital, Italy
Dev Prasad,
Fresenius Kabi, USA
Jozsef Dudas,
Innsbruck Medical University, Austria
*Correspondence:
Jingxin Mo
mojingx3@mail.sysu.edu.cn
Honglian Dai
daihonglian@whut.edu.cn
†These authors have contributed
equally in this paper.
Specialty section:
This article was submitted to
Pharmacology of Anti-Cancer Drugs,
a section of the journal
Frontiers in Pharmacology
Received: 29 October 2016
Accepted: 24 January 2017
Published: 14 February 2017
Citation:
Li B, Li Q, Mo J and Dai H (2017)
Drug-Loaded Polymeric
Nanoparticles for Cancer Stem Cell
Targeting. Front. Pharmacol. 8:51.
doi: 10.3389/fphar.2017.00051
Drug-Loaded Polymeric
Nanoparticles for Cancer Stem Cell
Targeting
Binbin Li1,2†, Qinghua Li3†, Jingxin Mo4,5* and Honglian Dai1,2*
1 State Key Laboratory of Advanced Technology for Materials Synthesis and Processing, Wuhan University of Technology,
Wuhan, China, 2 Biomedical Materials and Engineering Research Center of Hubei Province, Wuhan, China, 3 Department of
Neurology, Affiliated Hospital of Guilin Medical University, Guilin, China, 4 Key Laboratory for Stem Cells and Tissue
Engineering (Sun Yat-sen University), Ministry of Education, Guangzhou, China, 5 Department of Histology and Embryology,
Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
Cancer stem cells (CSCs) have been reported to play critical roles in tumor initiation,
propagation, and regeneration of cancer. Nano-size vehicles are employed to deliver
drugs to target the CSCs for cancer therapy. Polymeric nanoparticles have been
considered as the most efficient vehicles for drug delivery due to their excellent
pharmacokinetic properties. The CSCs specific antibodies or ligands can be conjugated
onto the surface or interior of nanoparticles to successfully target and finally eliminate
CSCs. In this review, we focus on the approaches of polymeric nanoparticles design for
loading drug, and their potential application for CSCs targeting in cancer therapy.
Keywords: cancer stem cell, drug-loaded, polymeric nanoparticle, cancer therapy
INTRODUCTION
Cancer is widely viewed as the major reason of death in the world (El-Serag, 2001). Although
decades of efforts of research and billions of funding have enhanced our understanding of the
underlying mechanisms of tumorigenesis, cancer caused mortality remains running at a high level
nowadays (Oishi and Wang, 2011). Recent studies have suggested that, the growth of tumors is
similar to that of normal proliferative tissues, fueled by limited numbers of dedicated stem cells
that are capable of self-renewal, called cancer stem cells (CSCs) (Reya et al., 2001; Clarke et al.,
2006; Adams and Strasser, 2008; Dick, 2009; Wilson et al., 2009; He et al., 2016).
The concept of CSCs was introduced firstly in Bonnet and Dick (1997). CSCs have been
identified in multiple malignancies, which are capable of self-renewal, and drive the propagation
and development of a tumor (Jordan et al., 2006; Rosen and Jordan, 2009; O’Brien et al., 2010;
Clevers, 2011). Due to these crucial roles, failure to efficiently eliminate CSCs during conventional
therapy may lead to tumor relapse and metastases. Thus, CSCs are considered as a critical issue
to be addressed in the cancer therapy (Dean et al., 2005; Li et al., 2015). Quite a lot of efforts
have been put into the study of anti-CSCs strategies to completely eliminate the CSCs population,
and some approaches have gained encouraging therapeutic outcomes, such as inhibiting the
signaling pathways related to self-renewal to interfere the CSCs proliferation and tumor growth,
breaking the tumor microenvironment to decrease the interaction between CSCs and cytokines,
and targeting the markers on CSCs surface to locate and destroy CSCs etc. (Beck and Blanpain,
2013; Chen et al., 2013; Lu et al., 2016). Within these strategies, the hottest research in the field of
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cancer therapy is CSCs targeting, because of its ability to improve
the survival of cancer patients, especially patients with drug
resistance in recent years (Zhou et al., 2009).
However, the sensitivity of the drug changed usually in the
tumor due to either genetic or epigenetic alterations (Zahreddine
and Borden, 2013). This would lead to acquired resistance
following the change of gene expression patterns, and eventually
drug selection during cancer treatment. Drug resistance results in
a series of problems including: the increase of CSCs population,
disease relapse and tumor metastasis during the period of cancer
treatment (Zhou et al., 2009; Takebe et al., 2011).
A large number of efforts have been done to minimize the
harmful impacts of drugs during the process of cancer therapy
(Vinogradov and Wei, 2012): (a) preventing the side effects on
the nearby cells and tissues; (b) increasing the drug accumulation
and efficacy in the lesion; (c) developing novel drug delivery and
targeting systems.
The key factor to solve these issues above is to allow the
CSCs exposed to the high enough drug concentration in cellular
environment. Numerous novel drug delivery strategies have
been developed with the rapid advances of nanotechnology. The
nanosized drug delivery system can be designed to conquer
the known disadvantages of the anticancer drugs, for instance,
the low bioavailability and high cytotoxic side effects (Gupta
et al., 2009; Kim et al., 2010). In one case, a novel nanogel-drug
conjugates based on membranotropic cholesteryl-HA (CHA) has
been synthesized for efficient targeting and suppression of drug-
resistant tumors. These conjugates could significantly increase
the bioavailability of poorly soluble drugs with previously
reported activity against CSC, such as etoposide, salinomycin,
and curcumin. The resultant CHA-drug nanogels demonstrated
higher cytotoxicity in CD44-expressing drug-resistant human
breast and pancreatic adenocarcinoma cells compared to that of
free drugs and non-modified HA-drug conjugates. Approaches
using polymeric nanoparticles to encapsulate drugs for CSC
targeting attract more attentions in cancer treatment because
of the advantages including the controllable release of drugs,
structural design for targeting, and functional design for
diagnosis (Wei et al., 2013).
In this review, we first introduce the specific characteristics
of CSCs and the common strategies for CSCs targeting. We
then outline the current polymeric nanoparticles used for CSCs
targeting in the application of cancer therapy.
CURRENT CANCER THERAPY VIA CSCS
INHIBITION
With the recent exploration advancing in CSCs, the CSCs
targeted therapy has brought a new hope to the cancer patients.
The identification and characterization of CSCs have revealed
numerous strategies of cancer treatment in-depth via specific
molecular therapies (Visvader and Lindeman, 2008): for example,
interfering the cell growth microenvironment of a tumor;
targeting the specific biomarkers of CSCs; or inhibiting the key
signaling pathways to interfere CSCs activity. Strategies of CSCs
targeting based on their properties were showed in Figure 1.
Targeting the Tumor Microenvironment
A niche is the CSCs intrinsic property built by tumor
microenvironment to prevent from apoptosis by chemotherapy.
The CSCs niche is a dynamic supportive system with specific
anatomic and functional features to modulate how the cells take
part in the process of tumor growth and metabolism (Scadden,
2006).
Folkins et al. (2007) reported that instead of targeting the CSCs
directly, attacking the vascular niche to collapse the resistance
ability of tumor against the chemotherapy. In another case,
Gulotta et al. (2007) suggested that in order to destroy the drug-
resistant brain tumor, to attack the key member of CSCs niche-
endothelial cells indirectly would be a promising strategy. The
anti-inflammatory drugs (IFN-β) could also serve as potential
components of CSC-focused therapies to disrupt the vascular
niche of glioma CSCs (Williams et al., 2010).
Whereas neither antiangiogenic nor tumor cell cytotoxic
effects alone are sufficient to reduce the CSCs fraction, therapies
combining these effects are capable of selectively eliminating
CSCs from the tumor. The possible reason for these observations
is that antiangiogenic therapies disrupt a glioma CSCs vascular
niche. The subsequent loss in communication between CSCs
and their niche would elicit a reduction or loss of certain
stem cell characteristics, which could include aspects of stem
cell-associated drug resistance, and may result in increased
proliferation rate and reduced DNA repair capacity in CSCs.
Such changes would sensitize the CSCs to the cytotoxic effects of
cyclophosphamide, therefore allowing combinatorial therapies to
selectively eliminate CSCs.
Inhibition of CSCs-Dependent Signaling
Pathways
The maintenance of stem cell nature partly depends on the
regulation of relative signaling pathways. Several signaling
pathways have been implicated in CSC chemoresistance in a
variety of cancers. The pathways and signal molecules related to
the control of CSCs self-renewal, differentiation and apoptosis
include PI3K/Akt, PTEN, JAK/STAT, Wnt/β-catenin, hedgehog,
Notch, and NF-κB etc. as shown in Figure 2 (Gulotta et al., 2007;
Baud and Karin, 2009; Burger and Peled, 2009; Chen et al., 2009;
Guo et al., 2010; Lorenzo et al., 2010; Roy et al., 2010; Murphy
and Stordal, 2011).
The activation of signal molecule Akt plays a critical role
for cellular transformation and tumorigenesis. The PI3K/Akt
signaling pathway regulated the growth of numerous cancers.
Guo et al.’s (2010) study showed that Akt1 improved the
resistance to apoptosis by increasing the expression level of
Bcl-2 and the phosphorylation of the pro-apoptotic protein
BAD. The tumor generation related signaling pathway JAK/STAT
was activated at the same time. To control the suppressor
of cytokine signaling-3 (SCS-3) is also viewed as an effective
method to regulate tumor formation by the activating JAK/STAT
signaling pathway (Pradhan et al., 2007). The Notch signaling
pathways have also been shown to be involved in tumor
development, metastatic initiation and self-renewal processes.
The over expression of Notch3 could lead to the expansion
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FIGURE 1 | Strategies of CSCs targeting. Strategies of CSCs targeting based on its specific molecular properties include: interfering the growth
microenvironment, targeting the biomarkers, inhibiting the key signaling pathways, targeting cell differentiation, targeting immune system and targeting metabolism.
of CSCs and chemoresistance enhancement in ovarian cancer.
The sensitivity of CSC was obvious increased to platinum
therapy after inhibiting the Notch signaling pathway via siRNA
knockout. In addition, the well-known hedgehog and Wnt
signaling pathways also play fundamental roles in maintaining
CSC populations (Dontu et al., 2011).
Targeting CSC-Dependent Markers
With the recent advances and growing knowledge on unique
CSC biomarkers, tumor targeted therapy has shed new light to
the cancer patients. The expressions of CSC surface markers,
however, are heterogenous, which are different from patients with
the same cancer and the same tumor in different progress stages.
Thus, it’s critical to evaluate the CSC markers in the tumor of
every stage to pick up the CSC relative treatment. Furthermore,
the CSC surface marker proteins play important roles not only
in cell isolation, identification and observation, but also in the
applications of both preclinical diagnosis and clinical therapy
(Visvader and Lindeman, 2008).
These markers include CD34, CD44, CD90, CD133, and
EpCAM, etc. (Medema, 2013). The ligands or antibodies against
tumor surface makers have been widely employed to enhance the
specificity of therapeutic strategies. The anti-bodies of these CSCs
biomarkers were developed and utilized in several drug delivery
systems for tumor targeting and cancer therapy. Bourseau-
Guilmain et al. (2011) prepared lipoprotein-like nanocapsules
to deliver AC133 to effectively target CD133 positive CSCs.
A CD44-specific tumor-targeting drug was carried by HA
for the cancer therapy (Marhaba et al., 2008). An anti-CD90
antibody was also proved to be able to stop the bone marrow-
derived multipotent stromal cells to differentiate into chondro-,
osteogenic, or adipo-lineages (Gundlach et al., 2011).
Interfering the CSCs Differentiation
Although the anticancer drugs for ideal targeting have being
looked for decades, only few are successfully applied in clinical
trial. One of them is all-trans retinoic acid (ATRA), Warrell et al.
(1993) found that the differentiation of leukemic promyelocytes
were blocked and failed to differentiate into mature granulocytes
after treating the patients with ATRA. The rational theory of
ATRA therapy is ATRA could drive the CSCs to differentiate from
stem cell into non-CSCs (e.g., epithelial cells). This case indicated
the therapy of interfering CSCs differentiation may be an effective
way to treat other forms of cancers. Other agents such as
phorbol myristate acetate (Carey et al., 1996), hexamethylamine
bisacetamide (Wu et al., 1991), dimethylsulfoxide (Arcangeli
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FIGURE 2 | Signal pathways related with cancer stem cells. Pathways and elements involved in the control of selfrenewing and differentiation of cancer stem
cells as well as normal stem cells include PI3K/Akt, JAK/STAT, Wnt/β-catenin, hedgehog, Notch, NF-κB, and so on.
et al., 1993) and vitamin D3 (Olsson et al., 1984) also were
reported to have the similar function in CSCs differentiation
therapy.
Immunotherapy against CSCs
Challenges in CSCs targeting remain intractable issues need
to be faced in a long term, while immunotherapy becomes a
novel potential interest in the field of cancer therapy. Numerous
researches have shown that CSCs can be eradicated by innate
immune effector cells. The usage of tumor antigens to directly
break the cancer patient’s immune system has been explored
decades for cancer therapy (Pardoll, 2012). The strategies
include: (a) using the specific peptides derived from tumor
antigens for cancer vaccination; (b) stimulating the immune cells
with dendritic-cells to fight against specific antigens; and (c)
interfering the immune responses of anti-tumor via retardant.
The CSCs-secreted TGF-β that has additional immuno-
suppressive effects on other subclasses of T lymphocytes, was
used to avoid being attacked by various cellular components
of the immune system (Pardoll, 2012). Castriconi et al. (2009)
indicated that the allogeneic and autologous-activated natural
killer cells were capable of influencing the stem-like cells to lysis.
Todaro et al. (2009) research demonstrated that γδT lymphocytes
can be used to kill human colon CSCs in vitro. Contag et al. (2010)
reported that the oncolytic virus can be delivered into lymphoma
cancer stem like cells as vehicles via cytokine-induced killer cells.
Exploiting Metabolic Differences to
Target CSCs
The behaviors of CSCs in the niche are affected by the metabolic
products, the CSCs therefor can respond to the conditional
environment. Because of the fresh discoveries in the Warburg
effect, cancer metabolism has been coming back into spotlight
the recent 10 years. This presents that cancer cells generate
ATP through glycolysis (even under non-hypoxic conditions)
rather than oxidative phosphorylation (Warburg et al., 1952).
Another research reported that they set up a mouse model of
lung CSCs and proved repressive functions of LKB1 on metastasis
through regulation of NEDD9 and found that LKB1 mutation
correlates with lung CSCs. These findings establish that LKB1
suppresses lung tumorigenesis through at least three independent
mechanisms influencing tumor initiation, differentiation, and
metastasis (Ji et al., 2007). With the development of novel
therapeutics based on the continuous studies on signaling
regulating metabolic pathways, the role of cell metabolism
is shedding new light in cancer research. For instance, the
metabolism of cancer cells can be changed via inhibiting the
mTOR signaling by hypoxia (Wouters and Koritzinsky, 2008).
Inhibiting the mevalonate metabolic pathway which plays vital
role in breast CSCs generation by hydroxy-3-methylglutaryl CoA
reductase blockers significantly break the CSCs growth process
(Ginestier et al., 2012). These cases indicated that tuning the CSC
metabolism could be considered as an effective way to interfere
the CSCs activities by specific targeting and kill the CSC cells
from the normal cells.
The CSCs extend our horizons of knowledge on cancer and
provide a new approach to eradicate malignancies. It is proved
that CSCs exist in various malignancies and play critical role
in tumor initiation and development. While the conventional
cancer therapy ways which are effective in various cancer
treatments, have no more obvious effect in chemo- and radio-
resistant cancer stem cells. Thus, a wide variety of CSCs targeting
strategies are being investigated for the treatment of malignant
tumors. What’s more, the unique characteristics of CSCs remain
needed to be further explored to promote the understanding and
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utilization of CSCs. The strategies mentioned above are just a
part of ways effectively used in CSCs targeting therapy. Although
promising, the challenges of specificity and potential toxicities
still need to be further tackled before the clinical trials. The
drugs used for CSCs targeting based on their characteristics may
have some adverse effects on the maintenance of normal cells or
organs. Therefore, it will be critically important to develop new
therapies that exclusively target CSCs and avoid targeting normal
stem cells or cells in the future.
POLYMERIC DRUG-LOADED
NANOPARTICLE DELIVERY SYSTEM
Although the huge progress emerges in medical technique, the
cancer therapy remains a challenging because of the low cure
rate. The polymeric drug-loaded nanoparticles have been viewed
as a novel promising strategy for cancer treatment because they
not only can improve the drug pharmacokinetics but also further
response to the permeation and retention (EPR) effect to enhance
the accumulation of drugs at the site of the tumor during cancer
treatment (Kapoor et al., 2015).
There are lots of factors should be included in an ideal
design of polymeric nanoparticles system for drug delivery,
including biocompatibility, particle size, drug loading rate,
and pharmacokinetics, etc. (Vinogradov and Wei, 2012). The
nanoparticles make themselves better cell affinity and easier
uptake by the target cells through interactions ligands on the
nanoparticles’ surface with receptors on the cell membranes.
There are numerous advantages of nanoparticles using for
anti-cancer drugs delivery in cancer treatment: (a) Increase
the drug circulation half-lives: Polyethylene glycol, polyvinyl
alcohol, polysaccharides, and surfactants such as poloxamer were
used to decorate the surface of nanovehicles to circumvent the
opsonization and the reticuloendothelial system. Cargos in these
nanovehicles turned into decreased apparent clearance, extended
apparent circulation half-life, as well as lessen apparent volume
of distribution, eventually producing prolonged drug retention
time in the circulation system. (b) Improve the drug aqueous
solubility and stability: nanotechnologies are broadly drawing
attention as favorable option for oral administration of drugs with
poor oral bioavailability. Besides increasing drug uptake via cell-
mediated active absorption (Florence, 2005), drug encapsulated
nanoparticles could diminish transporter-mediated eﬄux (Ling
et al., 2010). Additionally, drug loaded in nanoparticles protects
the drug from degrading by harsh conditions in the GI system
(Italia et al., 2007; Mittal and Kumar, 2009) and decreases
hepatic first-pass metabolism (Anand et al., 2007; Mittal et al.,
2007). Drug loaded in nanoparticles could safely go through the
gastrointestinal tract and liver avoiding degradation/metabolism,
which would result in reduction of the metabolic clearance and
increasing of its absorption and oral bioavailability as well. (c)
Control the drug release and specific targeting: some of the
most amazing advantages of nanocarriers include their tunable
payload release and the ability to specifically target their payload
to diseased tissues and cells by modification of their surface
chemistries, and finally their ability to respond to various internal
and external stimuli for “triggered” release to achieve temporal
and spatial control over the release of therapeutic payloads. (d)
Enhance the drug bioavailability: nanotechnology is increasingly
considered to be the technology of the future. Among the
wide applications of nanotechnology is the use of nanoparticles
for enhancing the bioavailability. Poorly water-soluble drug
candidates encountered in drug discovery cause increasing
problems of poor and variable bioavailability. It was suggested
that nanoparticles could enhance the oral drug bioavailability
probably because the special stability (thermodynamic and
kinetic stability) facilitate the safe transport of drugs through the
G1 tract and/or the mucoadhesivity of nanoparticles prolonging
the residence time in the gut, and the P-gp inhibitors contributing
to drug accumulation.
Designs of Nanoparticles for Drug
Delivery System
Although the traditional cancer therapy techniques are
improving and various novel therapeutic strategies are being
developed, polymeric nanoparticles are still viewed as the
first option for drug delivery and also widely used in the
research of other diseases due to their excellent physicochemical
properties (Fonseca et al., 2013, 2014), such as particle size,
surface charge, surface chemistry, hydrophobicity, degree of
rigidity, and degradation speed. The polymeric nanoparticles
also can be decorated on the surface to obtain the appropriate
functions to fit the tumor environment or properties of drugs.
The usual modification includes surface charge modification,
bioactive peptides graft, amphipathic compound graft and siRNA
(Figure 3).
Surface modification of polymeric nanoparticles has been
proved to be useful in offering multi-functionality, and cannot
only easily optimize the nanoparticles distribution in cells
and tissues, but also promote cellular uptake or reduce
cellular interactions. The modified polymeric nanoparticles can
accumulate the loaded-drugs within the tumor tissues accurately
and avoid damaging the nearby healthy tissues.
Particle Size
One of the most widely utilized mechanisms of drug delivery
system for targeting is based on particle size. The enhanced
EPR effect allows nanoparticles less than 500 nm to penetrate
tumor vasculature and gather in the regions of tumor (Petros and
Desimone, 2010). The larger nanoparticles would be prevented
getting there because they are trapped in the lungs or removed
out the body by the reticuloendothelial system (RES). The
nanoparticles are usually modified to obtain neutral surface
charge by coating hydrophilic molecules such as PEG to eliminate
particle aggregation and avoid RES for the EPR effect (Torchilin,
2011).
Transferrin
Transferrin (Tf) is a glycoprotein used to improve targeting
efficiency for the tumor cells which overexpress the Tf-receptor
by grafting to nanoparticles made of poly(L-lysine) (Wagner
et al., 1990), polyethyleneimine (Ogris et al., 2003), cyclodextrin
(Bellocq et al., 2003), or polyamidoamine (Huang et al., 2007).
Frontiers in Pharmacology | www.frontiersin.org 5 February 2017 | Volume 8 | Article 51
fphar-08-00051 February 10, 2017 Time: 14:46 # 6
Li et al. CSCs Targeting by Nanoparticles
FIGURE 3 | The usual surface modifications of polymeric nanoparticles. The usual modification includes surface charge modification, bioactive peptides graft,
amphipathic compound graft, and siRNA, etc.
Tf was reported to be conjugated onto the surface of PEI and
PEI-PEG nanoparticles for plasmid delivery, which showed the
clear improvement of tumor targeting and reduction on off-
target transfection (Hildebrandt et al., 2003). Tf conjugated to
cyclodextrin-PEG nanoparticles (CALAA-01) for the delivery of
small interfering RNA (siRNA) to solid tumors is undergoing
FDA Phase I clinical trials (Davis, 2009).
Epidermal Growth Factor Receptor
The epidermal growth factor receptor (EGFR), which considered
as a signal of poor prognosis, overexpressed in approximately
30% of solid tumors during cancer therapy (Jones et al., 2006).
The EGFR targeted polymeric nanoparticles were shown to
improve tumor specific transfection compared to non-targeted
nanoparticles (Kathrin et al., 2011).
RGD Peptide
The RGD peptide (arginine, glycine, aspartic acid) is reported
to strongly target the αvβ3 integrin receptor which is selectively
expressed in tumor vasculature to enhance the cellular uptake,
and weakly bind to some other integrin receptors (Kunath et al.,
2003). PBAE nanoparticles attached by RGD peptide for the
targeted delivery of DNA to tumor cells was proved to improve
transfection of cells overexpressing integrin receptors (Green
et al., 2007). Both the RGD peptide and cyclic-RGD peptide
conjugated to nanoparticles for targeted delivery of plasmids to
tumor cells has also been shown to improve transfection in vivo
for 24 h after IV administration in mice (Sakae et al., 2008).
Antibodies
Antibodies can be employed to specifically target a tumor
that expresses a tumor specific antigen. PEI conjugated with
HER2 antibodies for DNA delivery improved transfection against
HER2+ breast cancer cell lines in vitro (Chiu et al., 2004).
PEI/DNA nanoparticles conjugated with antibodies of prostate
specific membrane antigen for targeting prostate cancer cells
in vivo was reported to have a 20 times enhancement compared
to non-targeted nanoparticles (Moffatt et al., 2006).
In additionally, Folate (Zhang et al., 2010), HA (Needham
et al., 2012), and some specific carbohydrates have been
also employed as targeting moieties for appropriate polymeric
nanoparticle delivery to CSCs.
The increasing attentions on approaches of cancer treatments
have raised the research interest of CSCs targeting via polymeric
nanoparticle. The use of ligands conjugated to the surface of
nanoparticles can allow the drugs enter CSCs and regulate lots of
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genes or protein expression, kill the CSCs eventually. To improve
the transfection efficiency and the capacity of cellar uptake, the
factors such as ligand density, surface charge and affinity have to
be considered in the process of material design.
Applications of Polymeric Nanoparticles
for CSCs Targeting Therapy
Polymeric nanoparticles have been regarded as the most efficient
carriers for drug delivery due to their excellent pharmacokinetic
properties such as drug loading, drug release, structure stability
and nanoparticles degradation (Alexis et al., 2010; Pérez-Herrero
and Fernández-Medarde, 2015). The recent research hotspot of
polymers utilized for drug loaded nanoparticles include poly
(D, L-lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), poly
(ethylene glycol) (PEG), chitosan (CS), and hyaluronic acid (HA),
etc.
Poly (lactide-co-glycolide)
Poly (lactide-co-glycolide) (PLGA) is one of the few US FDA
approved polymers for clinical applications due to its outstanding
properties such as biodegradability and biocompatibility
(Chaubal, 2002; Astete and Sabliov, 2006). So far, it’s the most
widely used synthetic polymers in drug-loaded nanoparticles
development for cancer therapy (Biondi et al., 2008). Ni et al.
(2015) also reported that the CD133 grafted PLGA nanoparticles
loaded with salinomycin were capable to target the CD133+
osteosarcoma CSCs.
To kill both the normal cancer cells and CSCs, salinomycin
(SLM) and paclitaxel (PTX) were embedded by PGLA for CD44
targeted chemotherapy with emulsion solvent diffusion method.
This combinational therapy demonstrated the synergistic effects
of dramatically reducing the CD44+ cells (Muntimadugu et al.,
2016). In order to eliminate drug resistance and relapse of breast
CSCs, Swaminathan et al. (2013) prepared PLGA nanoparticles
to target CD133 via conjugating an anti-CD133 monoclonal
antibody. The result showed that the breast CSCs population was
significantly reduced and the therapeutic efficacy was obviously
enhanced. To further actively target CSCs to reduce their drug
resistance and stabilizing agent, HA and PF127 were conjugated
onto PLGA to get the smart nanoparticles for cancer therapy.
These nanoparticles were synthesized using the double-emulsion
approach and allowing for acidic pH-triggered drug release and
thermal responsiveness at the same time (Wang et al., 2015).
Hyaluronic Acid
Hyaluronic acid (HA) is an anionic, non-sulfated
glycosaminoglycan distributed in connective, epithelial
and neural tissues. HA has been widely studied in cancer
treatment by conjugating different drugs due to its outstanding
characteristics including biocompatibility, biodegradability,
and non-immunogenicity (Luo et al., 2000; Prestwich, 2011).
Many drug-resistant cancer cells and CSCs were reported to
enhance the expression levels of some biomarker receptors.
These markers conjugated onto HA can use to target CSCs
for the cancer therapy. For instance, cholesterol-modified
HA (CHA) conjugated with selected drugs that are highly
active against CSCs via biodegradable covalent linkage can
be used to deliver the drug efficiently for drug-resistant
cancer. Banzato et al. (2008) developed a paclitaxel-hyaluronan
bioconjugate (ONCOFIDTM-P, 20% drug content) to target
human ovarian cancer IGROV-1 and OVCAR-3 xenografts via
the intraperitoneal administration. The HA was also structurally
functionalized for siRNAs encapsulation to transfect siRNAs into
cancer cells that overexpress CD44 receptors. Several HA based
drug-loaded nanoparticles delivery systems have been delivered
into the cancer cells overexpressed the CD44 receptors, and some
decorated HA derivatives can effectively silence the related gene
activity in vitro and in vivo (Choi et al., 2009).
However, there is a defect of HA-based drug delivery
nanoparticles in cancer therapy application. The delivery
system preferentially accumulates in the liver after systemic
administration. To address this issue, poly (ethylene glycol) is
employed to conjugate onto HA. The result indicated that the
PEG-modified HA-nanoparticles were significantly reduced in
the liver, and lengthened the times stay in blood circulation,
eventually enhanced the veracity of CSCs targeting (Choi et al.,
2011).
Poly (ethylene glycol)
Poly (ethylene glycol) (PEG) is a hydrophilic polymer widespread
use in the field of biomedicine due to its excellent water solubility,
chain mobility, non-toxicity, and non-immunogenicity. In order
to solve the low water solubility and unstable properties of
bortezomib in clinical application, the amphiphilic copolymer
poly (ethylene glycol)-block-poly(d,l-lactide) (PEG-b-PLA)
nanoparticles were engineered. Their study demonstrated
that the bortezomib loaded in PEG-b-PLA nanoparticles can
enter into the targeted CSCs, and induce the CSCs apoptosis
and death. This DDS was proved to keep the drugs in CSCs
for a long time and accumulate the drugs in lesion tissue,
and eventually inhibit the proliferation of CSCs, promote
the therapeutic efficacy in breast cancer therapy (Shen et al.,
2015). To lower the toxicity and improve the drug release,
the diblock copolymer nanoparticles of poly (ethylene glycol)
(PEG) and functional polycarbonates (PAC) were fabricated
via metal-free organocatalytic ring-opening polymerization to
provide the narrow size distribution and high loading capacity
for anticancer drugs. Doxorubicin (DOX)-loaded PEG/PAC
nanoparticles showed higher antitumor efficacy and decreased
toxicity than free DOX in vivo (Ke et al., 2014). To increase the
solubility, the potent vascular-disrupting agent was bonded to
a PEG-based polymer to achieve self-assemble in the aqueous
solution. DOX then was loaded into these nanoparticle carriers
to improve the cytotoxicity and loading capacity. The in vivo
study on MCF-7 tumor bearing nude mice demonstrated that
the antitumor efficiency was significantly improved (Vinogradov
and Wei, 2012). To make the PEG nanoparticles intelligent, Liu
et al. (2013) developed the gelatinases-stimuli poly (ethylene
glycol)-peptide-poly(ε-caprolactone) drugs delivery system.
The nanoparticles were developed to investigate the targeting
effects on CSCs and non-stem cancer cells by carrying both
miR-200c and docetaxel (DOC). The results demonstrated
that the tumors growth speed was decreased after the miR-
200c/DOC nanoparticles were put into the nude mice. The
Frontiers in Pharmacology | www.frontiersin.org 7 February 2017 | Volume 8 | Article 51
fphar-08-00051 February 10, 2017 Time: 14:46 # 8
Li et al. CSCs Targeting by Nanoparticles
PEG-based gelatinases-response drug-loaded nanoparticles may
also suggest that the loading of both drugs and siRNA can
target not only CSCs but also non-stem cancer cells at the same
time.
Polylactic Acid
polylactic acid (PLA) is FDA approved biodegradable polymer
and fumaric acid existed in the Kreb cycle. It can be totally
excreted through metabolism after degradation. Yang et al.
(2015) established lung cancer stem-like cells (CSLCs)-targeting
encapsulated docetaxel PLA nanoparticles for anti-metastatic
therapy. The in vitro and in vivo experimental results confirmed
the outstanding anti-metastatic performance of CSLC-targeting
DTX nanoparticle. Liang et al. (2015) also have the similar
study, they fabricated the PLA nanoparticles loading DTX
based on the emulsion solvent evaporation method. Their study
indicated that the tumor growth inhibition and anti-metastatic
efficacy in the SCLC targeting drug delivery system for cancer
treatment. Pandey et al. (2015) developed PLA nanoparticles
to deliver quercetin (Qt) to inhibit the human breast cancer
cells. Results showed that the PLA-Qt nanoparticles displayed
excellent sustained release kinetics and can be used as a novel
vehicle for the cancer treatment. In another case, the cellulose,
that was reported to protect drugs and deliver them to the
target site, was grafted on poly (L-lactic acid) (PLLA) to load
betulinic acid for anti-cancer therapy. Results demonstrated that
the experimental effect in the CEg-PLLA/BA nanoparticles group
showed not only fewer side effects but also better efficacy in
tumor proliferation suppression than that of BA alone (Dai et al.,
2014). To regulate the signal molecules related to breast CSCs,
the MPEG-b-PLA nanoparticles were developed to deliver the
small molecules (Ahmed and Discher, 2004; Blanco et al., 2007).
Low-dose of DAC encapsulation can decrease the number of
CSCs in mammospheres of MDA-MB-231 cells and rectify their
sensitivity to DOX. While systemic delivery of DAC cannot only
obviously decrease the expression level of DNMT1 and DNMT3b
in a MB-MDA-231 xenograft murine model, but also up-regulate
the caspase-9 expression to enhance the sensitivity of CSCs
to DOX. The controllable MPEG-b-PLA nanoparticles loading
capacity offers a promising strategy for breast cancer therapy (Li
et al., 2014).
Chitosan
Chitosan, derived from chitin, is a positive biocompatible
and biodegradable natural polysaccharide. It is widely used
in the field of biomedicine including drug and gene delivery,
tissue engineering, wound healing, and antimicrobial (S˛enel and
Mcclure, 2004; Riva et al., 2011). The chitosan nanoparticles were
developed for targeting the overexpressed CD44 receptors on
CSLCs. The nanoparticles around 20 nm were delivered into the
tumor to actively target and be internalized in CD44+ CSLCs
by EPR effect. The drugs in nanoparticles then would release
out and diffuse into the cytosol, eventually accumulate in the
nuclei to produce cytotoxicity to kill CSLCs eventually (Chauhan
et al., 2012; Sykes et al., 2014). To lower the toxicity of platinate,
Nascimento et al. (2015) developed the chitosan-based polymeric
nanoparticles to encapsulate hydrophobic drugs by grafting
PEG and peptides. Their study reported that the modified
platinate encapsulated into chitosan-based nanoparticles can
obviously decreased the toxicity in cells. The chitosan also
can be used as cell recognition. A doxorubicin-encapsulated
polymeric nanoparticles decorated with chitosan on the surface
were developed to specifically target the CD44 receptors of
the cancer treatment. This nanoparticle system released the
doxorubicin in acidic environments localized in the cellular
endosomes/lysosomes to achieve the goal of killing the CSCs (Rao
et al., 2015).
In summary, a large number of polymeric nanoparticles
with different physicochemical characteristics for multiple drugs
loading have been developed to control the drugs release via
responding internal or external stimuli to significantly improve
therapeutic efficacy by CSCs targeting.
CONCLUSION AND PROSPECTS
Cancer is one of the most complicated diseases. Although
the drug-loaded nanoparticles have improved preclinical and
clinical outcomes for cancer treatment, the therapeutic efficacy
is still limited due to the genetic diversity and the biological
complexity of tumor. Therefore, modifying the chemical or
physical characteristics of polymeric nanoparticles to meet
the need of different drugs with different physicochemical
characteristics is an attractive strategy for clinical CSCs targeting.
In this review, we introduce the ways of CSCs inhibition based
on the CSCs profiles. Then we enumerate several representative
decorated polymeric nanoparticles for drugs delivery in the
applications of cancer therapy.
More and more studies have confirmed the CSCs is critical
factor for tumor resilience, resisting to radiotherapy, and were
accused for tumor Resurrection. As that knowledge about CSC
advanced, cutting-edge ideas and technologies have kept coming
forth in order to eliminate malignancies. Several kinds of
carcinomas may harbor CSCs with mesenchymal properties, and
self-renewal and multi-differentiation properties, while it’s hard
to find an exclusive selection marker to isolate and target the
corresponding CSCs. Fractions of CSCs could be masked by a
tumor with heterogeneousness, that indicate targeting treatment
for CSC isn’t a simple task. Therefore, many different targeted
therapies for systemic treatment for CSCs have been put forward
recently. The studies mainly focused on inhibition of the VEGF
and mTOR pathways and targeted on markers (such as CD105
and CXCR4) of CSCs. Although various fresh trials have been
carried out in clinic, there are still observable restrictions occur in
getting to CSCs in vivo due to the unreachability of the deep area
of tumor or because of the tumor milieu, these restrictions could
be overpowered by nanotechnological strategies. Versatile CSC-
targeting approaches together with newly discovered pathway
and cytotoxic agents could contribute to tackle those difficulties
in CSCs remedy. Accumulating knowledge on CSCs will lead us
to comprehensively understand the responses of CSCs to various
treatments, different phases of disease, and individual patient.
Finally, all of these finding would bring about more patient-
tailored and targeted treatments. Sensibly built-up nano-therapy
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for CSCs explores new routes for clinical study and brings in new
faith in practical use.
In the recent years, the hot research interest mainly focusses
on design of novel polymeric nanoparticle-based therapies for
CSC targeting in cancer treatment. Polymeric nanoparticles can
be expediently modified with the cell-recognizable moieties on
their surfaces, and designed in appropriate size and structure for
pharmaceutical applications. The polymeric nanoparticle-based
approaches have increased the drug safety, controllable drug
release, and targeting efficacy, and lowered the immunogenicity
and tumorigenesis.
Novel therapeutic strategies for combination therapy and
stimuli-activated drug delivery are also the representative of new
therapeutic trends. For instance, to deliver two or more drugs
simultaneously would improve different tumor growth-related
signaling pathways targeting, leading to a synergistic therapy
effect.
However, these approaches are still in the early stages
of development and have many theoretical and technical
limitations, issues of dose-related toxicity and side effects are
also needed to be addressed. Furthermore, the innovative in vitro
evaluation system has to be improved to accurately predict the
in vivo pharmacokinetics of drugs in humans. In spite of small
animal models have been used to evaluate the therapeutic effect,
it is far away from a perfect predictor of the drug efficacy in
humans.
The revolutionary developments of novel drugs and new drug
delivery systems are urgently needed, and the in vitro models
and in vivo pharmacokinetic profiles also need to be improved
to enhance the CSCs targeting for the cancer therapeutic effect.
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